Low-dose (7.5 mg/kg) bevacizumab may be a viable option in recurrent ovarian cancer: A retrospective study

Basit Öğe Kaydı
dc.contributor.authorDemirkiran, Aykut
dc.contributor.authorEryilmaz, Melek Karakurt
dc.contributor.authorKaraagac, Mustafa
dc.contributor.authorAraz, Murat
dc.contributor.authorKorkmaz, Mustafa
dc.contributor.authorKocak, Mehmet Zahid
dc.contributor.authorArtac, Mehmet
dc.date.accessioned2024-02-23T14:37:53Z
dc.date.available2024-02-23T14:37:53Z
dc.date.issued2023
dc.departmentNEÜen_US
dc.description.abstractObjective: Bevacizumab (BEV) is a humanized monoclonal antibody of vascular endothelial growth factor receptors and, as a result of clinical trials, was approved for the treatment of recurrent ovarian cancer (ROC). The aim of this study was to assess the clinical utility of BEV in patients with ROC in real-world practice beyond clinical trials. Materials and Methods: In this single-center retrospective cohort study, we evaluated the medical data of all patients with ROC who were treated with BEV between October 2013 and March 2020. Results: A total of 76 females were evaluated. Forty-nine (64.5%) patients were platinum sensitive and 27 (35.5%) patients were platinum resistant. BEV was used in combination with chemotherapy agents in all patients, and the most preferred combinations were gemcitabine/carboplatin (GC) (78.9%) and carboplatin/paclitaxel (14.5%). In all patients, the BEV dose was 7.5 mg/kg every 3 weeks. The median progression-free survival (PFS) was 11.1 months (95% confidence interval [CI]: 9.6-12.6), and the median overall survival (OS) was 22.3 months (95% CI: 17.5-27.2). In multivariate analysis, serous histological type (P = 0.01), maintenance BEV administration (P = 0.001), and combination of GC-BEV (P < 0.001) were associated with better PFS, while serous histological type (P = 0.016) and good performance status (P = 0.006) were associated with prolonged OS. Conclusions: Low-dose (7.5 mg/kg) BEV was found to be effective in the second-line treatment of patients with ROC in our real-life study. In addition, the combination of BEV with GC was shown to be a viable option, especially in the treatment selection of platinum-resistant patients.en_US
dc.identifier.doi10.4103/jcrt.jcrt_1879_20
dc.identifier.endpage600en_US
dc.identifier.issn0973-1482
dc.identifier.issn1998-4138
dc.identifier.issue3en_US
dc.identifier.pmid37470581en_US
dc.identifier.scopus2-s2.0-85165371231en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage595en_US
dc.identifier.urihttps://doi.org/10.4103/jcrt.jcrt_1879_20
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16253
dc.identifier.volume19en_US
dc.identifier.wosWOS:001062420500014en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofJournal Of Cancer Research And Therapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBevacizumaben_US
dc.subjectRecurrent Ovarian Canceren_US
dc.subjectSurvivalen_US
dc.titleLow-dose (7.5 mg/kg) bevacizumab may be a viable option in recurrent ovarian cancer: A retrospective studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu